Could a Half-Dose of aspirin protect elderly hearts just as well?

NCT ID NCT07542860

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a lower daily dose of aspirin (50 mg) is as effective and safer than the standard dose (100 mg) for preventing heart attacks and strokes in Chinese patients aged 60 and older with heart disease. Researchers will follow over 5,400 participants for up to 6 years, tracking major heart events and bleeding complications. The goal is to find the best balance between preventing clots and avoiding bleeding in older adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Aspirin (50 mg vs 100 mg daily)
What this could lead to
If successful, this could show that a lower aspirin dose is safer and equally effective for preventing heart attacks and strokes in elderly patients.
What could go wrong
This is an observational extension of an existing study, not a randomized trial, so results may be less definitive. The lower dose might not prevent cardiovascular events as well as the standard dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University First Hospital

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.